{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T22:33:54Z","timestamp":1784673234597,"version":"3.55.0"},"reference-count":120,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thebreastonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Breast"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1016\/j.breast.2016.11.021","type":"journal-article","created":{"date-parts":[[2016,12,5]],"date-time":"2016-12-05T22:49:26Z","timestamp":1480978166000},"page":"224-232","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":46,"special_numbering":"C","title":["BRCA mutation genetic testing implications in the United States"],"prefix":"10.1016","volume":"31","author":[{"given":"Soley","family":"Bayraktar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Banu","family":"Arun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"17","key":"10.1016\/j.breast.2016.11.021_bib1","doi-asserted-by":"crossref","first-page":"7006","DOI":"10.1158\/0008-5472.CAN-08-0599","article-title":"The relative contribution of point mutations and genomic rearrangements in BRCA1 and BRCA2 in high-risk breast cancer families","volume":"68","author":"Palma","year":"2008","journal-title":"Cancer Res"},{"issue":"12","key":"10.1016\/j.breast.2016.11.021_bib2","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1001\/jama.295.12.1379","article-title":"Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer","volume":"295","author":"Walsh","year":"2006","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.breast.2016.11.021_bib3","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1200\/JCO.2011.41.0027","article-title":"Prevalence and type of BRCA mutations in hispanics undergoing genetic cancer risk assessment in the southwestern United States: a report from the clinical cancer genetics community research network","volume":"31","author":"Weitzel","year":"2013","journal-title":"J\u00a0Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"11","key":"10.1016\/j.breast.2016.11.021_bib4","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1093\/jnci\/91.11.943","article-title":"Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer","volume":"91","author":"Peto","year":"1999","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"6","key":"10.1016\/j.breast.2016.11.021_bib5","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1002\/(SICI)1097-0142(20000315)88:6<1393::AID-CNCR17>3.0.CO;2-P","article-title":"Frequency of BRCA1\/BRCA2 mutations in a population-based sample of young breast carcinoma cases","volume":"88","author":"Malone","year":"2000","journal-title":"Cancer"},{"issue":"16","key":"10.1016\/j.breast.2016.11.021_bib6","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1093\/jnci\/93.16.1215","article-title":"Family history of breast and ovarian cancers and BRCA1 and BRCA2 mutations in a population-based series of early-onset breast cancer","volume":"93","author":"Loman","year":"2001","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"8","key":"10.1016\/j.breast.2016.11.021_bib7","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.ejca.2005.11.032","article-title":"BRCA1, BRCA2 and TP53 mutations in very early-onset breast cancer with associated risks to relatives","volume":"42","author":"Lalloo","year":"2006","journal-title":"Eur J Cancer"},{"issue":"10","key":"10.1016\/j.breast.2016.11.021_bib8","first-page":"1301","article-title":"Anglian breast cancer study group","volume":"83","author":"Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases","year":"2000","journal-title":"Br J cancer"},{"issue":"5645","key":"10.1016\/j.breast.2016.11.021_bib9","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1126\/science.1088759","article-title":"New York Breast Cancer Study G. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2","volume":"302","author":"King","year":"2003","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.breast.2016.11.021_bib10","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s10549-012-2348-2","article-title":"Evaluation of BRCA1 mutations in an unselected patient population with triple-negative breast cancer","volume":"137","author":"Rummel","year":"2013","journal-title":"Breast Cancer Res Treat"},{"issue":"8","key":"10.1016\/j.breast.2016.11.021_bib11","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1136\/jmedgenet-2011-100006","article-title":"Prevalence of BRCA1 and BRCA2 mutations in triple negative breast cancer","volume":"48","author":"Evans","year":"2011","journal-title":"J\u00a0Med Genet"},{"issue":"1","key":"10.1016\/j.breast.2016.11.021_bib12","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s10549-012-2021-9","article-title":"Prevalence of BRCA1 mutations among 403 women with triple-negative breast cancer: implications for genetic screening selection criteria: a hellenic cooperative oncology group study","volume":"134","author":"Fostira","year":"2012","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"10.1016\/j.breast.2016.11.021_bib13","doi-asserted-by":"crossref","first-page":"R2","DOI":"10.1186\/bcr419","article-title":"BRCA1 and BRCA2 mutations in a population-based study of male breast cancer","volume":"4","author":"Basham","year":"2002","journal-title":"Breast Cancer Res"},{"issue":"1","key":"10.1016\/j.breast.2016.11.021_bib14","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/ng0596-123","article-title":"BRCA2 germline mutations in male breast cancer cases and breast cancer families","volume":"13","author":"Couch","year":"1996","journal-title":"Nat Genet"},{"issue":"3","key":"10.1016\/j.breast.2016.11.021_bib15","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1023\/B:JOMG.0000048770.90334.3b","article-title":"The genetic epidemiology of breast cancer genes","volume":"9","author":"Thompson","year":"2004","journal-title":"J\u00a0mammary Gl Biol neoplasia"},{"issue":"2","key":"10.1016\/j.breast.2016.11.021_bib16","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1002\/cncr.29041","article-title":"Cancers associated with BRCA1 and BRCA2 mutations other than breast and ovarian","volume":"121","author":"Mersch","year":"2015","journal-title":"Cancer"},{"issue":"9","key":"10.1016\/j.breast.2016.11.021_bib17","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1200\/JCO.2002.09.023","article-title":"The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2","volume":"20","author":"Lakhani","year":"2002","journal-title":"J\u00a0Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"11","key":"10.1016\/j.breast.2016.11.021_bib18","doi-asserted-by":"crossref","first-page":"3396","DOI":"10.1200\/JCO.1999.17.11.3396","article-title":"Survival in hereditary breast cancer associated with germline mutations of BRCA2","volume":"17","author":"Verhoog","year":"1999","journal-title":"J\u00a0Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"2","key":"10.1016\/j.breast.2016.11.021_bib19","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJMoa070608","article-title":"Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations","volume":"357","author":"Rennert","year":"2007","journal-title":"N.\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.breast.2016.11.021_bib20","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/j.ejca.2006.12.009","article-title":"Tumour characteristics, survival and prognostic factors of hereditary breast cancer from BRCA2-, BRCA1- and non-BRCA1\/2 families as compared to sporadic breast cancer cases","volume":"43","author":"Brekelmans","year":"2007","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1016\/j.breast.2016.11.021_bib21","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s10549-007-9781-7","article-title":"Distant disease-free interval, site of first relapse and post-relapse survival in BRCA1- and BRCA2-associated compared to sporadic breast cancer patients","volume":"111","author":"Kriege","year":"2008","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"10.1016\/j.breast.2016.11.021_bib22","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s10549-006-9288-7","article-title":"Prognosis of early-onset breast cancer based on BRCA1\/2 mutation status in a French population-based cohort and review","volume":"101","author":"Bonadona","year":"2007","journal-title":"Breast Cancer Res Treat"},{"issue":"24","key":"10.1016\/j.breast.2016.11.021_bib23","doi-asserted-by":"crossref","first-page":"4045","DOI":"10.1200\/JCO.2000.18.24.4045","article-title":"Germline BRCA1\/2 mutations and p27(Kip1) protein levels independently predict outcome after breast cancer","volume":"18","author":"Chappuis","year":"2000","journal-title":"J\u00a0Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"5","key":"10.1016\/j.breast.2016.11.021_bib24","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1002\/ijc.22789","article-title":"Surveillance for familial breast cancer: differences in outcome according to BRCA mutation status","volume":"121","author":"Moller","year":"2007","journal-title":"Int J Cancer"},{"issue":"1","key":"10.1016\/j.breast.2016.11.021_bib25","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s10549-010-0859-2","article-title":"Effect of BRCA1\/2 mutation on short-term and long-term breast cancer survival: a systematic review and meta-analysis","volume":"122","author":"Lee","year":"2010","journal-title":"Breast Cancer Res Treat"},{"issue":"14","key":"10.1016\/j.breast.2016.11.021_bib26","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1002\/cncr.25911","article-title":"Clinical outcome of triple negative breast cancer in BRCA1 mutation carriers and noncarriers","volume":"117","author":"Lee","year":"2011","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.breast.2016.11.021_bib27","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s10549-011-1711-z","article-title":"Outcome of triple-negative breast cancer in patients with or without deleterious BRCA mutations","volume":"130","author":"Bayraktar","year":"2011","journal-title":"Breast Cancer Res Treat"},{"issue":"8","key":"10.1016\/j.breast.2016.11.021_bib28","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1002\/cncr.29903","article-title":"Twenty-one-gene recurrence score assay in BRCA-associated versus sporadic breast cancers: differences based on germline mutation status","volume":"122","author":"Shah","year":"2016","journal-title":"Cancer"},{"issue":"16","key":"10.1016\/j.breast.2016.11.021_bib29","doi-asserted-by":"crossref","first-page":"3807","DOI":"10.1158\/1078-0432.CCR-15-0931","article-title":"Effects of BRCA1\/2 on ovarian and breast cancer survival\u2013response","volume":"21","author":"Zhong","year":"2015","journal-title":"Clin cancer Res Off J Am Assoc Cancer Res"},{"key":"10.1016\/j.breast.2016.11.021_bib30","first-page":"33","article-title":"Impact of prior knowledge of mutation status on tumor stage in BRCA1\/2 mutation carriers with newly diagnosed breast cancer","author":"Yam","year":"2015","journal-title":"J\u00a0Clin Oncol Off. J Am Soc Clin Oncol"},{"issue":"12","key":"10.1016\/j.breast.2016.11.021_bib31","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1200\/JCO.2004.04.033","article-title":"Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers","volume":"22","author":"Metcalfe","year":"2004","journal-title":"J\u00a0Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"7","key":"10.1016\/j.breast.2016.11.021_bib32","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1200\/JCO.2007.12.6078","article-title":"Predictors of contralateral prophylactic mastectomy in women with a BRCA1 or BRCA2 mutation: the hereditary breast cancer clinical study group","volume":"26","author":"Metcalfe","year":"2008","journal-title":"J\u00a0Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"3","key":"10.1016\/j.breast.2016.11.021_bib33","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/sj.bjc.6602703","article-title":"Risk reduction of contralateral breast cancer and survival after contralateral prophylactic mastectomy in BRCA1 or BRCA2 mutation carriers","volume":"93","author":"van Sprundel","year":"2005","journal-title":"Br J cancer"},{"issue":"1","key":"10.1016\/j.breast.2016.11.021_bib34","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s10549-013-2583-1","article-title":"Contralateral mastectomy improves survival in women with BRCA1\/2-associated breast cancer","volume":"140","author":"Evans","year":"2013","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"10.1016\/j.breast.2016.11.021_bib35","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1002\/ijc.29032","article-title":"Improved overall survival after contralateral risk-reducing mastectomy in BRCA1\/2 mutation carriers with a history of unilateral breast cancer: a prospective analysis","volume":"136","author":"Heemskerk-Gerritsen","year":"2015","journal-title":"Int J Cancer"},{"key":"10.1016\/j.breast.2016.11.021_bib36","doi-asserted-by":"crossref","first-page":"g226","DOI":"10.1136\/bmj.g226","article-title":"Contralateral mastectomy and survival after breast cancer in carriers of BRCA1 and BRCA2 mutations: retrospective analysis","volume":"348","author":"Metcalfe","year":"2014","journal-title":"BMJ"},{"issue":"15","key":"10.1016\/j.breast.2016.11.021_bib37","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1200\/JCO.2013.53.2820","article-title":"Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation","volume":"32","author":"Finch","year":"2014","journal-title":"J\u00a0Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"21","key":"10.1016\/j.breast.2016.11.021_bib38","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1056\/NEJMoa012158","article-title":"Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations","volume":"346","author":"Rebbeck","year":"2002","journal-title":"N.\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.breast.2016.11.021_bib39","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1001\/jama.296.2.185","article-title":"Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation","volume":"296","author":"Finch","year":"2006","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.breast.2016.11.021_bib40","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djw177","article-title":"Bilateral oophorectomy and breast cancer risk in BRCA1 and BRCA2 mutation carriers","volume":"109","author":"Kotsopoulos","year":"2017","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"16","key":"10.1016\/j.breast.2016.11.021_bib41","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1200\/JCO.2005.02.7888","article-title":"Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1\/2-associated stage I\/II breast cancer","volume":"24","author":"Pierce","year":"2006","journal-title":"J\u00a0Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.breast.2016.11.021_bib42","doi-asserted-by":"crossref","unstructured":"Metcalfe K, Lynch HT, Ghadirian P, Tung N, Kim-Sing C, Olopade OI, et\u00a0al. Risk of ipsilateral breast cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat.127(1):287\u2013296.","DOI":"10.1007\/s10549-010-1336-7"},{"issue":"9245","key":"10.1016\/j.breast.2016.11.021_bib43","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1016\/S0140-6736(00)03258-X","article-title":"Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group","volume":"356","author":"Narod","year":"2000","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.breast.2016.11.021_bib44","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1093\/jnci\/djn442","article-title":"Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers","volume":"101","author":"Rebbeck","year":"2009","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.breast.2016.11.021_bib45","doi-asserted-by":"crossref","unstructured":"Domchek SM, Friebel TM, Singer CF, Evans DG, Lynch HT, Isaacs C, et\u00a0al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA.304(9):967\u2013975.","DOI":"10.1001\/jama.2010.1237"},{"issue":"206","key":"10.1016\/j.breast.2016.11.021_bib46","article-title":"Is risk-reducing mastectomy in BRCA1\/2 mutation carriers with a history of unilateral breast cancer beneficial with respect to distant disease free survival and overall survival?","volume":"8","author":"Heemskerk-Gerritsen","year":"2010","journal-title":"Eur J Cancer Suppl"},{"key":"10.1016\/j.breast.2016.11.021_bib47","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/1471-2407-8-101","article-title":"Coordinated prophylactic surgical management for women with hereditary breast-ovarian cancer syndrome","volume":"8","author":"Batista","year":"2008","journal-title":"BMC Cancer"},{"issue":"3 Pt 1","key":"10.1016\/j.breast.2016.11.021_bib48","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1097\/01.AOG.0000228959.30577.13","article-title":"Prophylactic bilateral salpingo-oophorectomy compared with surveillance in women with BRCA mutations","volume":"108","author":"Schmeler","year":"2006","journal-title":"Obstet Gynecol"},{"issue":"9","key":"10.1016\/j.breast.2016.11.021_bib49","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1002\/ijc.21536","article-title":"Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: an update","volume":"118","author":"Gronwald","year":"2006","journal-title":"Int J Cancer"},{"issue":"1","key":"10.1016\/j.breast.2016.11.021_bib50","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/cncr.20728","article-title":"Appropriateness of breast-conserving treatment of breast carcinoma in women with germline mutations in BRCA1 or BRCA2: a clinic-based series","volume":"103","author":"Robson","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.breast.2016.11.021_bib51","doi-asserted-by":"crossref","unstructured":"Malone KE, Begg CB, Haile RW, Borg A, Concannon P, Tellhed L, et\u00a0al. Population-based study of the risk of second primary contralateral breast cancer associated with carrying a mutation in BRCA1 or BRCA2. J Clin Oncol Off J Am Soc Clin Oncol.28(14):2404\u20132410.","DOI":"10.1200\/JCO.2009.24.2495"},{"key":"10.1016\/j.breast.2016.11.021_bib52","doi-asserted-by":"crossref","unstructured":"Reding KW, Bernstein JL, Langholz BM, Bernstein L, Haile RW, Begg CB, et\u00a0al. Adjuvant systemic therapy for breast cancer in BRCA1\/BRCA2 mutation carriers in a population-based study of risk of contralateral breast cancer. Breast Cancer Res Treat.123(2):491\u2013498.","DOI":"10.1007\/s10549-010-0769-3"},{"issue":"1","key":"10.1016\/j.breast.2016.11.021_bib53","doi-asserted-by":"crossref","first-page":"R8","DOI":"10.1186\/bcr658","article-title":"A\u00a0combined analysis of outcome following breast cancer: differences in survival based on BRCA1\/BRCA2 mutation status and administration of adjuvant treatment","volume":"6","author":"Robson","year":"2004","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.breast.2016.11.021_bib54","doi-asserted-by":"crossref","first-page":"3091","DOI":"10.1200\/JCO.2012.47.8313","article-title":"Tamoxifen may reduce contralateral cancers in BRCA mutation carriers","volume":"31","author":"Phillips","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.breast.2016.11.021_bib55","series-title":"Differential outcomes in patients treated with endocrine therapy for early or locally advanced breast cancer based on BRCA mutation status ASCO 2009","year":"2009"},{"issue":"9","key":"10.1016\/j.breast.2016.11.021_bib56","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1038\/bjc.2011.120","article-title":"Predictors of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers","volume":"104","author":"Metcalfe","year":"2011","journal-title":"Br J cancer"},{"key":"10.1016\/j.breast.2016.11.021_bib57","unstructured":"Shafaee MN G-BA, Lin HY, Arun B. Aromatase inhibitors and the risk of contralateral breast cancer in BRCA mutation carriers. ASCO breast cancer symposium, A3 oral presentation."},{"key":"10.1016\/j.breast.2016.11.021_bib58","unstructured":"of ACSGftED, http:\/\/www.cancer.org\/healthy\/findcancerearly\/cancerscreeningguidelines\/CAf, american-cancer-society-guidelines-for-theearly-, detection-of-cancer. Accessed December 6."},{"issue":"1","key":"10.1016\/j.breast.2016.11.021_bib59","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jacr.2009.09.022","article-title":"Breast cancer screening with imaging: recommendations from the Society of Breast Imaging and the ACR on the use of mammography, breast MRI, breast ultrasound, and other technologies for the detection of clinically occult breast cancer","volume":"7","author":"Lee","year":"2010","journal-title":"J\u00a0Am Coll Radiology JACR"},{"issue":"17","key":"10.1016\/j.breast.2016.11.021_bib60","doi-asserted-by":"crossref","first-page":"3900","DOI":"10.1002\/cncr.25971","article-title":"Effectiveness of alternating mammography and magnetic resonance imaging for screening women with deleterious BRCA mutations at high risk of breast cancer","volume":"117","author":"Le-Petross","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.breast.2016.11.021_bib61","unstructured":"NCCN GFH-RABaO, Available CPGiOv, http:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/f, genetics_screening.pdf. Accessed December 9."},{"issue":"3","key":"10.1016\/j.breast.2016.11.021_bib62","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/S0025-7125(05)70253-4","article-title":"Cancer surveillance of patients from familial pancreatic cancer kindreds","volume":"84","author":"Brentnall","year":"2000","journal-title":"Med Clin N. Am"},{"issue":"7","key":"10.1016\/j.breast.2016.11.021_bib63","first-page":"606","article-title":"Screening for pancreatic neoplasia in high-risk individuals: an EUS-based approach","volume":"2","author":"Canto","year":"2004","journal-title":"Clin gastroenterology hepatology Off Clin Pract J Am Gastroenterological Assoc"},{"key":"10.1016\/j.breast.2016.11.021_bib64","unstructured":"Cancer: UPSTFSC, http:\/\/www.ahrq.gov\/Accessed November 2, 2016."},{"issue":"5","key":"10.1016\/j.breast.2016.11.021_bib65","first-page":"733","article-title":"Fertility intentions following testing for a BRCA1 gene mutation","volume":"13","author":"Smith","year":"2004","journal-title":"Cancer Epidemiol biomarkers Prev Publ Am Assoc Cancer Res cosponsored by Am Soc Prev Oncol"},{"issue":"2","key":"10.1016\/j.breast.2016.11.021_bib66","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1002\/pon.1875","article-title":"The psychosocial impact of interrupted childbearing in long-term female cancer survivors","volume":"21","author":"Canada","year":"2012","journal-title":"Psychooncology"},{"issue":"4","key":"10.1016\/j.breast.2016.11.021_bib67","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.soncn.2009.08.002","article-title":"Cancer and its treatment effect on young breast cancer survivors","volume":"25","author":"Camp-Sorrell","year":"2009","journal-title":"Semin Oncol Nurs"},{"issue":"2","key":"10.1016\/j.breast.2016.11.021_bib68","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1034\/j.1399-0004.2002.620204.x","article-title":"Family issues in a psychoeducation group for women with a BRCA mutation","volume":"62","author":"Speice","year":"2002","journal-title":"Clin Genet"},{"issue":"9193","key":"10.1016\/j.breast.2016.11.021_bib69","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1016\/S0140-6736(99)04336-6","article-title":"Pregnancy and risk of early breast cancer in carriers of BRCA1 and BRCA2","volume":"354","author":"Jernstrom","year":"1999","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.breast.2016.11.021_bib70","doi-asserted-by":"crossref","first-page":"R121","DOI":"10.1186\/bcr619","article-title":"BRCA2 mutation carriers, reproductive factors and breast cancer risk","volume":"5","author":"Tryggvadottir","year":"2003","journal-title":"Breast Cancer Res"},{"issue":"43","key":"10.1016\/j.breast.2016.11.021_bib71","doi-asserted-by":"crossref","first-page":"5832","DOI":"10.1038\/sj.onc.1209870","article-title":"Modifiers of risk of hereditary breast cancer","volume":"25","author":"Narod","year":"2006","journal-title":"Oncogene"},{"issue":"14","key":"10.1016\/j.breast.2016.11.021_bib72","first-page":"5420","article-title":"Modification of BRCA1- and BRCA2-associated breast cancer risk by AIB1 genotype and reproductive history","volume":"61","author":"Rebbeck","year":"2001","journal-title":"Cancer Res"},{"issue":"3","key":"10.1016\/j.breast.2016.11.021_bib73","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1097\/00001648-200205000-00004","article-title":"Breast cancer risk in Ashkenazi BRCA1\/2 mutation carriers: effects of reproductive history","volume":"13","author":"Hartge","year":"2002","journal-title":"Epidemiology"},{"issue":"5","key":"10.1016\/j.breast.2016.11.021_bib74","first-page":"272","article-title":"Modifying effect of reproductive risk factors on the age at onset of breast cancer for German BRCA1 mutation carriers","volume":"123","author":"Chang-Claude","year":"1997","journal-title":"J\u00a0Cancer Res Clin Oncol"},{"issue":"8","key":"10.1016\/j.breast.2016.11.021_bib75","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1093\/jnci\/djj132","article-title":"Pregnancies, breast-feeding, and breast cancer risk in the international BRCA1\/2 carrier cohort study (IBCCS)","volume":"98","author":"Andrieu","year":"2006","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"1","key":"10.1016\/j.breast.2016.11.021_bib76","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s10549-013-2729-1","article-title":"The impact of pregnancy on breast cancer survival in women who carry a BRCA1 or BRCA2 mutation","volume":"142","author":"Valentini","year":"2013","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.breast.2016.11.021_bib77","series-title":"prevention,and treatment","author":"MJGdaD","year":"2010"},{"issue":"29","key":"10.1016\/j.breast.2016.11.021_bib78","doi-asserted-by":"crossref","first-page":"4775","DOI":"10.1200\/JCO.2006.06.6100","article-title":"Cancer genetic testing and assisted reproduction","volume":"24","author":"Offit","year":"2006","journal-title":"J\u00a0Clin Oncol official J Am Soc Clin Oncol"},{"issue":"2","key":"10.1016\/j.breast.2016.11.021_bib79","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s10689-013-9685-0","article-title":"Comparison of attitudes regarding preimplantation genetic diagnosis among patients with hereditary cancer syndromes","volume":"13","author":"Rich","year":"2014","journal-title":"Fam cancer"},{"issue":"1","key":"10.1016\/j.breast.2016.11.021_bib80","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/ejhg.2011.146","article-title":"Attitudes to reproductive genetic testing in women who had a positive BRCA test before having children: a qualitative analysis","volume":"20","author":"Ormondroyd","year":"2012","journal-title":"Eur J Hum Genet"},{"issue":"6","key":"10.1016\/j.breast.2016.11.021_bib81","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1016\/j.fertnstert.2005.03.013","article-title":"Fertility preservation and reproduction in cancer patients","volume":"83","author":"Ethics Committee of the American Society for Reproductive M","year":"2005","journal-title":"Fertil Steril"},{"issue":"3","key":"10.1016\/j.breast.2016.11.021_bib82","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.ygyno.2008.11.039","article-title":"A\u00a0prospective study of quality of life among women undergoing risk-reducing salpingo-oophorectomy versus gynecologic screening for ovarian cancer","volume":"112","author":"Fang","year":"2009","journal-title":"Gynecol Oncol"},{"issue":"2","key":"10.1016\/j.breast.2016.11.021_bib83","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jmig.2009.12.016","article-title":"Bilateral oophorectomy versus ovarian conservation: effects on long-term women's health","volume":"17","author":"Parker","year":"2010","journal-title":"J\u00a0Minim Invasive Gynecol"},{"issue":"4","key":"10.1016\/j.breast.2016.11.021_bib84","doi-asserted-by":"crossref","first-page":"483","DOI":"10.3109\/13697137.2015.1020484","article-title":"Long-term health consequences of premature or early menopause and considerations for management","volume":"18","author":"Faubion","year":"2015","journal-title":"Climacteric"},{"issue":"3","key":"10.1016\/j.breast.2016.11.021_bib85","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1097\/gme.0b013e31822a9937","article-title":"Premature menopause or early menopause and risk of ischemic stroke","volume":"19","author":"Rocca","year":"2012","journal-title":"Menopause"},{"issue":"2","key":"10.1016\/j.breast.2016.11.021_bib86","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.maturitas.2009.08.003","article-title":"Premature menopause or early menopause: long-term health consequences","volume":"65","author":"Shuster","year":"2010","journal-title":"Maturitas"},{"issue":"19","key":"10.1016\/j.breast.2016.11.021_bib87","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1093\/jnci\/djn313","article-title":"Hormone therapy and the risk of breast cancer in BRCA1 mutation carriers","volume":"100","author":"Eisen","year":"2008","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"31","key":"10.1016\/j.breast.2016.11.021_bib88","doi-asserted-by":"crossref","first-page":"7804","DOI":"10.1200\/JCO.2004.00.8151","article-title":"Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group","volume":"23","author":"Rebbeck","year":"2005","journal-title":"J\u00a0Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.breast.2016.11.021_bib89","series-title":"Is hormone replacement therapy (HRT) following risk-reducing salpingo-oophorectomy (RRSO) in BRCA1 (B1)- and BRCA2 (B2)-mutation carriers associated with an increased risk of breast cancer?","author":"DSe","year":"2011"},{"issue":"1","key":"10.1016\/j.breast.2016.11.021_bib90","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1037\/0278-6133.16.1.63","article-title":"Psychological responses to BRCA1 mutation testing: preliminary findings","volume":"16","author":"Croyle","year":"1997","journal-title":"Health Psychol"},{"issue":"2","key":"10.1016\/j.breast.2016.11.021_bib91","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1200\/JCO.2002.20.2.514","article-title":"Impact of BRCA1\/BRCA2 mutation testing on psychologic distress in a clinic-based sample","volume":"20","author":"Schwartz","year":"2002","journal-title":"J\u00a0Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"6","key":"10.1016\/j.breast.2016.11.021_bib92","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1037\/0278-6133.21.6.564","article-title":"A\u00a0brief assessment of concerns associated with genetic testing for cancer: the Multidimensional Impact of Cancer Risk Assessment (MICRA) questionnaire","volume":"21","author":"Cella","year":"2002","journal-title":"Health Psychol"},{"issue":"3","key":"10.1016\/j.breast.2016.11.021_bib93","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1002\/ajmg.a.10102","article-title":"Genetic testing for a BRCA1 mutation: prophylactic surgery and screening behavior in women 2 years post testing","volume":"118A","author":"Botkin","year":"2003","journal-title":"Am J Med Genet A"},{"issue":"32","key":"10.1016\/j.breast.2016.11.021_bib94","doi-asserted-by":"crossref","first-page":"4302","DOI":"10.1200\/JCO.2010.33.1561","article-title":"Long-term reactions to genetic testing for BRCA1 and BRCA2 mutations: does time heal women's concerns?","volume":"29","author":"Halbert","year":"2011","journal-title":"J\u00a0Clin Oncol official J Am Soc Clin Oncol"},{"issue":"4","key":"10.1016\/j.breast.2016.11.021_bib95","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1037\/a0014778","article-title":"Emotional distress following genetic testing for hereditary breast and ovarian cancer: a meta-analytic review","volume":"28","author":"Hamilton","year":"2009","journal-title":"Health Psychol"},{"issue":"2","key":"10.1016\/j.breast.2016.11.021_bib96","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1002\/cncr.26294","article-title":"Long-term outcomes of BRCA1\/BRCA2 testing: risk reduction and surveillance","volume":"118","author":"Schwartz","year":"2012","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.breast.2016.11.021_bib97","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1200\/JCO.2002.20.5.1260","article-title":"Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers","volume":"20","author":"Scheuer","year":"2002","journal-title":"J\u00a0Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"5","key":"10.1016\/j.breast.2016.11.021_bib98","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1038\/sj.bjc.6603610","article-title":"Predictive genetic testing for BRCA1\/2 in a UK clinical cohort: three-year follow-up","volume":"96","author":"Foster","year":"2007","journal-title":"Br J cancer"},{"issue":"9","key":"10.1016\/j.breast.2016.11.021_bib99","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1001\/jamaoncol.2015.3048","article-title":"Utilization and outcomes of BRCA genetic testing and counseling in a national commercially insured population: the about study","volume":"1","author":"Armstrong","year":"2015","journal-title":"JAMA Oncol"},{"issue":"10","key":"10.1016\/j.breast.2016.11.021_bib100","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1200\/JCO.2004.04.086","article-title":"Impact of BRCA1\/BRCA2 counseling and testing on newly diagnosed breast cancer patients","volume":"22","author":"Schwartz","year":"2004","journal-title":"J\u00a0Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"2","key":"10.1016\/j.breast.2016.11.021_bib101","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s10549-008-0128-9","article-title":"Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients","volume":"115","author":"Byrski","year":"2009","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.breast.2016.11.021_bib102","doi-asserted-by":"crossref","unstructured":"Byrski T, Gronwald J, Huzarski T, Grzybowska E, Budryk M, Stawicka M, et\u00a0al. Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy. J Clin Oncol Off J Am Soc Clin Oncol.28(3):375\u2013379.","DOI":"10.1200\/JCO.2008.20.7019"},{"key":"10.1016\/j.breast.2016.11.021_bib103","doi-asserted-by":"crossref","unstructured":"Arun B, Bayraktar S, Liu DD, Gutierrez Barrera AM, Atchley D, Pusztai L, et\u00a0al. Response to neoadjuvant systemic therapy for breast cancer in BRCA mutation carriers and noncarriers: a single-institution experience. J Clin Oncol Off J Am Soc Clin Oncol.29(28):3739\u20133746.","DOI":"10.1200\/JCO.2011.35.2682"},{"key":"10.1016\/j.breast.2016.11.021_bib104","doi-asserted-by":"crossref","unstructured":"Silver DP, Richardson AL, Eklund AC, Wang ZC, Szallasi Z, Li Q, et\u00a0al. Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer. J Clin Oncol Off J Am Soc Clin Oncol.28(7):1145\u20131153.","DOI":"10.1200\/JCO.2009.22.4725"},{"issue":"4","key":"10.1016\/j.breast.2016.11.021_bib105","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1038\/onc.2008.405","article-title":"Decreased BRCA1 confers tamoxifen resistance in breast cancer cells by altering estrogen receptor-coregulator interactions","volume":"28","author":"Wen","year":"2009","journal-title":"Oncogene"},{"issue":"2","key":"10.1016\/j.breast.2016.11.021_bib106","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa0900212","article-title":"Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers","volume":"361","author":"Fong","year":"2009","journal-title":"N.\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.breast.2016.11.021_bib107","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s10549-014-3100-x","article-title":"Pathologic complete response to neoadjuvant cisplatin in BRCA1-positive breast cancer patients","volume":"147","author":"Byrski","year":"2014","journal-title":"Breast Cancer Res Treat"},{"issue":"4","key":"10.1016\/j.breast.2016.11.021_bib108","doi-asserted-by":"crossref","first-page":"R110","DOI":"10.1186\/bcr3231","article-title":"Results of a phase II open-label, non-randomized trial of cisplatin chemotherapy in patients with BRCA1-positive metastatic breast cancer","volume":"14","author":"Byrski","year":"2012","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.breast.2016.11.021_bib109","doi-asserted-by":"crossref","unstructured":"Kriege M, Jager A, Hooning MJ, Huijskens E, Blom J, van Deurzen CH, et\u00a0al. The efficacy of taxane chemotherapy for metastatic breast cancer in BRCA1 and BRCA2 mutation carriers. Cancer.118(4):899\u2013907.","DOI":"10.1002\/cncr.26351"},{"key":"10.1016\/j.breast.2016.11.021_bib110","unstructured":"weekly RogBsathrHdirtn, paclitaxel followed by anthracycline-based chemotherapy. Boughey JC et\u00a0al. San Antonio Breast Cancer Symposium 2015 aP\u2013."},{"issue":"8","key":"10.1016\/j.breast.2016.11.021_bib111","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1038\/sj.bjc.6600859","article-title":"BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells","volume":"88","author":"Tassone","year":"2003","journal-title":"Br J cancer"},{"issue":"9","key":"10.1016\/j.breast.2016.11.021_bib112","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.4161\/cc.5.9.2726","article-title":"BRCA1 downregulation leads to premature inactivation of spindle checkpoint and confers paclitaxel resistance","volume":"5","author":"Chabalier","year":"2006","journal-title":"Cell Cycle"},{"key":"10.1016\/j.breast.2016.11.021_bib113","doi-asserted-by":"crossref","unstructured":"Tutt A, Robson M, Garber JE, Domchek SM, Audeh MW, Weitzel JN, et\u00a0al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet.376(9737):235\u2013244.","DOI":"10.1016\/S0140-6736(10)60892-6"},{"key":"10.1016\/j.breast.2016.11.021_bib114","doi-asserted-by":"crossref","unstructured":"Audeh MW, Carmichael J, Penson RT, Friedlander M, Powell B, Bell-McGuinn KM, et\u00a0al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet.376(9737):245\u2013251.","DOI":"10.1016\/S0140-6736(10)60893-8"},{"issue":"3","key":"10.1016\/j.breast.2016.11.021_bib115","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1200\/JCO.2014.56.2728","article-title":"Olaparib monotherapy in patients with advanced cancer and a germline BRCA1\/2 mutation","volume":"33","author":"Kaufman","year":"2015","journal-title":"J\u00a0Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.breast.2016.11.021_bib116","series-title":"ASCO annual meeting JCO","article-title":"First-in-human trial of novel oral PARP inhibitor BMN 673 in patients with solid tumors","author":"De Bono","year":"2013"},{"issue":"1","key":"10.1016\/j.breast.2016.11.021_bib117","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1093\/annonc\/mdt384","article-title":"PARP Inhibitors for BRCA1\/2 mutation-associated and BRCA-like malignancies","volume":"25","author":"Lee","year":"2014","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.breast.2016.11.021_bib118","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1200\/JCO.2011.36.9215","article-title":"Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer","volume":"30","author":"Kaye","year":"2012","journal-title":"J\u00a0Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"1","key":"10.1016\/j.breast.2016.11.021_bib119","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ygyno.2010.05.033","article-title":"A\u00a0Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer","volume":"119","author":"Friedlander","year":"2010","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.breast.2016.11.021_bib120","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1611310","article-title":"Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer","author":"Mirza","year":"2016","journal-title":"N.\u00a0Engl J Med"}],"container-title":["The Breast"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977616302557?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977616302557?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T08:37:57Z","timestamp":1760776677000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960977616302557"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2]]},"references-count":120,"alternative-id":["S0960977616302557"],"URL":"https:\/\/doi.org\/10.1016\/j.breast.2016.11.021","relation":{},"ISSN":["0960-9776"],"issn-type":[{"value":"0960-9776","type":"print"}],"subject":[],"published":{"date-parts":[[2017,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"BRCA mutation genetic testing implications in the United States","name":"articletitle","label":"Article Title"},{"value":"The Breast","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.breast.2016.11.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}